HomeTechnology TransferTechnologiesDesign of Novel Molecules that Regulate Sirtuins
Technology Transfer

Design of Novel Molecules that Regulate Sirtuins

Inventor(s)

Brandi D. Sanders

Tech ID
MR07001
Key Words
age-related disease, diabetes, longevity, metabolic diseases, nicotinamide, rational drug design, Sir2, Sirtuins
Applications and Advantages

This technology provides a method for rational, structure-aided drug design to develop small molecules that target the regulatory nicotinamide binding site of Sir2 proteins. Sir2 modulators may be useful for the treatment of diabetes, obesity, Alzheimer’s, other neurodegenerative diseases, and diseases of aging.

Intellectual Property Status

U.S. Patent Application No. 12/023,287 (US-2008-0305496, published 12/11/2008); U.S. Patent Application No. 12/511,679 (US-2009-0326007, published 12/31/2009).

Licensing Opportunity

Wistar is seeking to collaborate with a corporate partner to use this technology to develop small molecule modulators of Sir2. An exclusive license or sponsored research to further develop the technology would be considered.

Relevant Publication(s)

Sanders, B.D.; Zhao,K.; Slama, J.T.; Marmorstein, R.; (2007) “Structural basis for nicotinamide inhibition and base exchange in Sir2 enzymes”. Mol Cell 25: 463-472